IOSP vs CBT

For growth investors, Innospec Inc.

(IOSP) is the stronger pick with -3. 7% revenue growth year-over-year, versus -7. 0% for Cabot Corporation (CBT). Cabot Corporation (CBT) offers the better valuation at 13. 5x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Cabot Corporation (CBT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cabot Corporation (CBT) is the cheapest at 13.

5x versus Innospec Inc. at 16. 4x. On forward P/E, Cabot Corporation is actually cheaper at 13. 0x.

Over the past 5 years, Cabot Corporation (CBT) delivered a total return of +43.

2%, compared to -18. 3% for Innospec Inc. (IOSP). Over 10 years, the gap is even starker: CBT returned +115. 7% versus IOSP's +84. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innospec Inc.

(IOSP) is the lower-risk stock at 0. 70β versus Cabot Corporation's 0. 78β — meaning CBT is approximately 12% more volatile than IOSP relative to the S&P 500. On balance sheet safety, Innospec Inc. (IOSP) carries a lower debt/equity ratio of 7% versus 71% for Cabot Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innospec Inc.

(IOSP) is pulling ahead at -3. 7% versus -7. 0% for Cabot Corporation (CBT). On earnings-per-share growth, the picture is similar: Innospec Inc. grew EPS 228. 9% year-over-year, compared to -10. 4% for Cabot Corporation. Over a 3-year CAGR, IOSP leads at -3. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cabot Corporation (CBT) is the more profitable company, earning 8.

9% net margin versus 6. 6% for Innospec Inc. — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CBT leads at 16. 7% versus 8. 8% for IOSP. At the gross margin level — before operating expenses — IOSP leads at 27. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Cabot Corporation (CBT) trades at 13.

0x forward P/E versus 15. 5x for Innospec Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IOSP: 50. 1% to $115. 00.

All stocks in this comparison pay dividends.

Innospec Inc. (IOSP) offers the highest yield at 2. 2%, versus 2. 2% for Cabot Corporation (CBT).

For long-horizon retirement investors, Innospec Inc.

(IOSP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), 2. 2% yield). Both have compounded well over 10 years (IOSP: +84. 4%, CBT: +115. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.